Clinical trials: Peanut Allergy
Peanut Allergy, Food Allergy
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
The investigators will perform a double blind, placebo controlled clinical trial with Xolair (omalizumab) at four centers to safely and rapidly desensitize patients with severe peanut allergy.
- Trial name
- PRROTECT (NCT01781637)
- Testing
- Omalizumab
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Boston Children's Hospital
Peanut Allergy
Salvage Peanut Oral Immunotherapy Study
The purpose of this trial is to study the safety of rescue peanut oral immunotherapy followed by the introduction of dietary peanut for patients with peanut allergy who have lost desensitization during a peanut immunotherapy…
- Trial name
- SOIT (NCT03251508)
- Testing
- Peanut OIT
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: To assess the efficacy of Viaskin Peanut after up to 36…
- Trial name
- OLFUS-VIPES (NCT01955109)
- Testing
- Viaskin Peanut 250 mcg
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 171 people
- Sponsor
- DBV Technologies
Peanut Allergy
Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy
The primary objective of the study is to assess the tolerability of peanut protein in pediatric patients (6-17 years old) treated with dupilumab monotherapy, in which tolerability is defined as the proportion of patients who…
- Trial name
- NCT03793608
- Testing
- Dupilumab
- Where
- 9 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Peanut Allergy
Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)
The purpose of this study is to demonstrate the efficacy and safety of AR101 through reduction in clinical reactivity to peanut allergen in peanut-allergic children and adults.
- Trial name
- PALISADE (NCT02635776)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 69 sites in United States, Canada and 8 more
- Volunteers
- 555 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
PALISADE Follow-on Study (ARC004)
The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.
- Trial name
- NCT02993107
- Testing
- AR101
- Where
- 65 sites in United States, Canada and 7 more
- Volunteers
- 388 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Hypersensitivity, Food Allergy
FARE Peanut SLIT and Early Tolerance Induction
Primary Objective: To determine if 36 months of peanut SLIT as an early intervention in subjects ages 1 to 4 years induces clinical desensitization.
- Conditions
- Peanut Hypersensitivity, Food Allergy, Food Hypersensitivity, Peanut Allergy
- Trial name
- FARE/SLIT (NCT02304991)
- Testing
- Liquid Peanut Extract
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of North Carolina, Chapel Hill
Peanut Allergy
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
- Trial name
- ARC001 (NCT01987817)
- Testing
- AR101 powder provided in capsules
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
This is a multi-center, open-label, follow-on study to gather additional information on the safety and tolerability of oral desensitization with CPNA in the subjects who participated in ARC001.
- Trial name
- NCT02198664
- Testing
- AR101 - Peanut protein capsule
- Where
- 8 sites in United States
- Volunteers
- 47 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES)
This is a multicenter, randomized, double-blind, placebo-controlled safety study of AR101 using the characterized oral desensitization immunotherapy (CODIT™) regimen in peanut-allergic children.
- Trial name
- RAMSES (NCT03126227)
- Testing
- AR101
- Where
- 67 sites in United States, Canada
- Volunteers
- 506 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
AR101 Real-World Open-Label Extension Study
This study is enrolling participants by invitation only. This is an open-label, safety extension study for subjects who participated in the ARC007 study.
- Trial name
- NCT03337542
- Testing
- AR101
- Where
- 60 sites in United States, Canada
- Volunteers
- 243 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
The objectives of this dose-finding study for the treatment of peanut allergy are: To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize…
- Trial name
- VIPES (NCT01675882)
- Testing
- Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- DBV Technologies
Peanut Allergy
ARTEMIS Peanut Allergy In Children
The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.
- Trial name
- ARTEMIS (NCT03201003)
- Testing
- AR101 powder provided in capsules & sachets
- Where
- 18 sites in France, Germany and 5 more
- Volunteers
- 175 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
Tolerance Following Peanut Oral Immunotherapy
The unifying objective of this project is to determine whether peanut oral immunotherapy (PN OIT) induced clinical tolerance in the context of food allergy is significantly associated with the expansion of a specific regulatory T…
- Trial name
- PNOIT2 (NCT01750879)
- Testing
- Peanut Flour, Oat Flour
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Massachusetts General Hospital
Peanut Allergy
Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents
To compare the HRQOL of AR101 characterized oral desensitization immunotherapy (CODIT™) in combination with standard of care (peanut avoidance, education) versus standard of care alone in peanut-allergic subjects aged 4 to 17…
- Trial name
- NCT03703791
- Testing
- AR101
- Where
- 11 sites in Spain
- Volunteers
- 1 people
- Sponsor
- Aimmune Therapeutics, Inc.
Peanut Allergy
High Threshold Peanut Challenge Study
This protocol is designed to better characterize a sub-population of peanut sensitized individuals who may be non-allergic, despite significant sensitization, or who may be allergic, but at high threshold doses.
- Trial name
- PAID-UP (NCT02698033)
- Testing
- Peanut flour, Toasted oat flour
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Peanut Allergy
The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
Determine whether peanut oral immunotherapy (OIT) induces clinical tolerance as assessed after the initial 3 month avoidance period Secondary Objectives: Identify the basic immune mechanisms which can explain the differences in…
- Trial name
- POISED (NCT02103270)
- Testing
- Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Stanford University
Peanut Hypersensitivity, Food Hypersensitivity
Sublingual Immunotherapy for Peanut Allergy and Induction of Tolerance
The goal of this study will be to increase the reaction threshold (desensitization) of peanut allergic children using peanut sublingual immunotherapy and to determine if the nonreactive state of the immune system persists after…
- Conditions
- Peanut Hypersensitivity, Food Hypersensitivity, Food Allergy, Peanut Allergy
- Trial name
- SLIT-TLC (NCT01373242)
- Testing
- Liquid peanut extract (Peanut SLIT)
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of North Carolina, Chapel Hill
Eczema, Egg Allergy
Promoting Tolerance to Peanut in High-Risk Children
This study will evaluate whether early exposure to peanuts promotes tolerance and provides protection from developing peanut allergy in children who are allergic to eggs or who have severe eczema.
- Conditions
- Eczema, Egg Allergy, Food Allergy
- Trial name
- LEAP (NCT00329784)
- Testing
- Peanut Consumption Group
- Where
- United Kingdom
- Volunteers
- 640 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Peanut Allergy
Oral Peanut Immunotherapy
Peanut allergy is one of the most serious food allergies because of its life long persistence, and the potential for severe allergic reactions.
- Trial name
- PNOIT (NCT01324401)
- Testing
- Peanut flour OIT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital